🔴 Adaptive Biotechnologies Corp is trading 4.3% down today on dilution concerns from $300M convertible notes and restructuring

Adaptive Biotechnologies Corp is trading 4.3% down at $16.48 today as investors weigh the impact of an upsized $300 million convertible notes offering and a major corporate restructuring.

• The company is splitting its operations into two distinct units—MRD diagnostics and Immune Medicine—in a strategic move to refocus on its core MRD business.
• Shares are under pressure following the pricing of $300 million in 0% convertible notes, which raised concerns regarding potential shareholder dilution despite being priced at a ~40% premium.
• The financing is intended to strengthen the company's liquidity position and provide the necessary capital to execute its business realignment.